Elutia (ELUT) Q2 2026 earnings summary

Executive summary

• Secured up to $26 million in non-dilutive funding, including a $15 million credit facility and SimpliDerm sale proceeds, to fund NXT-41x through FDA clearance and commercial launch, with no equity offering.

• Signed agreement to sell SimpliDerm for up to $11 million; cardiovascular divestiture process ongoing, sharpening focus on the drug-eluting biomatrix (DEB) platform.

• All resources and organizational focus are now directed toward NXT-41x, targeting a $1.5 billion U.S. market with high unmet need.

• Independent survey of 50 surgeons showed 96% interest in adopting NXT-41x and 92% willingness to champion it at their hospitals.

• Regulatory and manufacturing progress keeps NXT-41 and NXT-41x on track for FDA clearance and commercial readiness.

Financial highlights

• Q2 2026 net sales were $2.4 million, down from $2.7 million year-over-year, mainly due to SimpliDerm production disruption, offset by cardiovascular sales growth.

• GAAP gross margin improved to 59.6% from 52.9% year-over-year; adjusted gross margin rose to 70.7% from 62.7%.

• Operating expenses decreased to $9.4 million from $9.8 million, with lower litigation costs and higher R&D spend.

• Net loss improved to $7.6 million from $9.6 million year-over-year; adjusted EBITDA loss was $4.6 million versus $3.0 million.

• Ended the quarter with $19.9 million in cash, with up to $34 million more expected from transactions.

Outlook and guidance

• Funding runway secured through at least 2028, covering regulatory milestones and commercial launch.

• Anticipates FDA clearance for NXT-41 in Q4 2026 and for NXT-41x in H1 2027.

• Soft launch of NXT-41x planned for H2 2027, with full commercial launch in 2028.

• Company expects continued operating losses and negative cash flows as it advances product development.